Replimune Group (REPL)
(Delayed Data from NSDQ)
$6.42 USD
+0.27 (4.39%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.41 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.42 USD
+0.27 (4.39%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.41 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
by Zacks Equity Research
Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 70.6% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.
Is a Surprise Coming for Replimune (REPL) This Earnings Season?
by Zacks Equity Research
Replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Down -22% in 4 Weeks, Here's Why Replimune Group, Inc. (REPL) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Replimune Group, Inc. (REPL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 87.9% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Recent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's Why
by Zacks Equity Research
Replimune Group, Inc. (REPL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Replimune (REPL) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Replimune (REPL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.